Alkermes (ALKS) Expected to Announce Quarterly Earnings on Tuesday

Alkermes (NASDAQ:ALKS - Get Free Report) is expected to be releasing its Q2 2025 earnings data before the market opens on Tuesday, July 29th. Analysts expect Alkermes to post earnings of $0.42 per share and revenue of $343.20 million for the quarter. Alkermes has set its FY 2025 guidance at 1.030-1.210 EPS.

Alkermes (NASDAQ:ALKS - Get Free Report) last announced its earnings results on Thursday, May 1st. The company reported $0.13 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.19). The firm had revenue of $306.51 million during the quarter, compared to analyst estimates of $307.53 million. Alkermes had a return on equity of 27.52% and a net margin of 23.30%. The business's quarterly revenue was down 12.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.43 earnings per share. On average, analysts expect Alkermes to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Alkermes Stock Performance

Shares of NASDAQ ALKS traded down $0.14 during mid-day trading on Friday, reaching $29.22. The company had a trading volume of 1,398,214 shares, compared to its average volume of 1,726,710. The stock has a fifty day moving average of $30.03 and a two-hundred day moving average of $30.89. The company has a market capitalization of $4.82 billion, a price-to-earnings ratio of 13.98, a PEG ratio of 1.83 and a beta of 0.44. Alkermes has a 12-month low of $24.48 and a 12-month high of $36.45.

Insider Activity

In related news, SVP Christian Todd Nichols sold 3,334 shares of Alkermes stock in a transaction dated Tuesday, June 10th. The stock was sold at an average price of $31.09, for a total value of $103,654.06. Following the completion of the transaction, the senior vice president directly owned 86,208 shares of the company's stock, valued at $2,680,206.72. The trade was a 3.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 4.40% of the stock is owned by corporate insiders.

Institutional Trading of Alkermes

Several institutional investors and hedge funds have recently added to or reduced their stakes in ALKS. Ashton Thomas Private Wealth LLC acquired a new position in shares of Alkermes during the 1st quarter worth about $213,000. Royal Bank of Canada grew its position in shares of Alkermes by 117.2% in the 1st quarter. Royal Bank of Canada now owns 275,526 shares of the company's stock valued at $9,098,000 after purchasing an additional 148,696 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Alkermes by 4.3% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 482,332 shares of the company's stock valued at $15,927,000 after purchasing an additional 20,091 shares during the period. 95.21% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on ALKS. Wall Street Zen lowered shares of Alkermes from a "strong-buy" rating to a "buy" rating in a research report on Monday, May 5th. UBS Group raised shares of Alkermes from a "neutral" rating to a "buy" rating and lifted their price target for the company from $33.00 to $42.00 in a research report on Tuesday, June 17th. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Alkermes from $40.00 to $52.00 and gave the company a "buy" rating in a research report on Thursday, March 27th. The Goldman Sachs Group began coverage on shares of Alkermes in a research report on Tuesday. They issued a "buy" rating and a $43.00 price target on the stock. Finally, Robert W. Baird lifted their price target on shares of Alkermes from $38.00 to $41.00 and gave the company an "outperform" rating in a research report on Friday, May 2nd. Three research analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Alkermes has a consensus rating of "Moderate Buy" and an average target price of $40.92.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.